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Prevalence of b-lactamase-
producing bacteria in human
periodontitis
Rams TE, Degener JE, van Winkelhoﬀ AJ. Prevalence of b-lactamase-producing
bacteria in human periodontitis. J Periodont Res 2013; 48: 493–499. © 2012 John
Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Background and Objective: Beta-lactam antibiotics prescribed in periodontal
therapy are vulnerable to degradation by bacterial b-lactamases. This study eval-
uated the occurrence of b-lactamase-positive subgingival bacteria in chronic
periodontitis subjects of USA origin, and assessed their in vitro resistance to
metronidazole at a breakpoint concentration of 4 lg/mL.
Material and Methods: Subgingival plaque specimens from deep periodontal
pockets with bleeding on probing were removed from 564 adults with severe
chronic periodontitis before treatment. The samples were transported in VMGA
III and then plated onto: (i) nonselective enriched Brucella blood agar (EBBA)
and incubated anaerobically for 7 d; and (ii) selective trypticase soy-bacitracin-
vancomycin (TSBV) and incubated for 3 d in air + 5% CO2. At the end of the
incubation periods, the bacterial test species were identiﬁed and quantiﬁed. Spec-
imen dilutions were also plated onto EBBA plates supplemented with 2 lg/mL of
amoxicillin, a combination of 2 lg/mL of amoxicillin plus 2 lg/mL of the b-lac-
tamase inhibitor clavulanic acid, or 4 lg/mL of metronidazole, followed by
anaerobic incubation for 7 d. Bacterial test species presumptively positive for
b-lactamase production were identiﬁed by growth on EBBA primary isolation
plates supplemented with amoxicillin alone and no growth on EBBA primary
isolation plates containing both amoxicillin plus clavulanic acid. A subset of
such isolates was subjected to nitroceﬁn-based chromogenic disk testing to
conﬁrm the presence of b-lactamase activity. In vitro resistance to 4 lg/mL of
metronidazole was noted when growth of test species occurred on metronida-
zole-supplemented EBBA culture plates.
Results: Two-hundred and ninety-four (52.1%) of the study subjects yielded
b-lactamase-producing subgingival bacterial test species, with Prevotella
intermedia/nigrescens, Fusobacterium nucleatum and other Prevotella species most
frequently identiﬁed as b-lactamase-producing organisms. Of the b-lactamase-
producing bacterial test species strains recovered, 98.9% were susceptible in vitro
to metronidazole at 4 lg/mL.
Conclusion: The occurrence of b-lactamase-positive subgingival bacterial species
in more than half of the subjects with severe chronic periodontitis raises
questions about the therapeutic potential of single-drug regimens with b-lactam
antibiotics in periodontal therapy. The in vitro eﬀectiveness of metronidazole
against nearly all recovered b-lactamase-producing subgingival bacterial species
further supports clinical periodontitis treatment strategies involving the
combination of systemic amoxicillin plus metronidazole.
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Beta-lactamase production represents
a major virulence factor by which
pathogenic bacteria evade the broad-
spectrum antimicrobial eﬀects of b-lac-
tam antibiotics and perpetuate human
infections, including those in orofacial
tissues (1). Bacterial b-lactamases rap-
idly hydrolyze amide bonds within the
four-membered ring forming the
foundational structure of b-lactam
antibiotics, leaving them pharmacolog-
ically inactive as antimicrobial agents
that disrupt bacterial cell-wall peptido-
glycan biosynthesis (1).
Beta-lactamase activity has been
detected in subgingival sites of sub-
jects with chronic periodontitis at lev-
els capable of inactivating b-lactam
antibiotics passing into periodontal
pockets through gingival crevicu-
lar ﬂuid exudate (2). Subgingival
b-lactamase has been signiﬁcantly
correlated with increasing periodontal
probing depth measurements (2),
recent treatment with systemic penicillin
drugs (3), and carriage of b-lactamase-
encoding genes by microbial species
in subgingival plaque bioﬁlms (4).
Studies of patients with chronic
periodontitis in the USA (3–5), The
Netherlands (6,7), Spain (7), Norway
(8), France (9,10) and the UK (11)
have reported a 53.2–100% occur-
rence in subjects for subgingival b-lac-
tamase-producing bacteria, with
higher prevalence rates found in local-
ities with greater over-the-counter
access and consumption of systemic
antimicrobial agents (7). However,
these ﬁndings are limited by their
inclusion of relatively few study sub-
jects (12–47 patients with periodonti-
tis per study), who were mostly
dental-school patients and/or from
localized geographic regions that may
not necessarily be representative of
more diverse community populations.
For example, data from the USA on
the occurrence of subgingival b-lac-
tamase-producing bacterial species in
patients with chronic periodontitis is
presently derived from a total of 42
dental-school patients in Connecticut
and 25 in Florida (3,5).
As a result, there is a need to assess
subgingival b-lactamase-producing
bacteria in larger-sized subject groups
that are geographically distributed
beyond a single city or dental-school
patient population. The aim of the
present study was to evaluate the
occurrence of b-lactamase-positive
subgingival bacteria in 564 geographi-
cally distributed subjects in the USA
with chronic periodontitis and to
assess their in vitro resistance to met-
ronidazole at a breakpoint concentra-
tion of 4 lg/mL.
Material and methods
Subjects
A total of 564 adults (270 men and 294
women; age range, 33–91 years; mean
age standard deviation = 49.1  11.7
years), diagnosed with severe chronic
periodontitis (12) by periodontists in
private dental practices in the USA,
were included in the present study as
their subgingival plaque samples were
consecutively received for microbiolog-
ical analysis by the Oral Microbiology
Testing Service (OMTS) Laboratory at
Temple University School of Dentistry,
Philadelphia (PA, USA). Three-
hundred and ﬁfty-four (62.8%) of the
study subjects originated from Mary-
land (n = 174), Pennsylvania (n = 91),
New Jersey (n = 51), Delaware
(n = 25), Virginia (n = 7) and the Dis-
trict of Columbia (n = 6) in the mid-
Atlantic region of the USA, with all
others from Connecticut (n = 48),
Florida (n = 35), Illinois (n = 20), 11
other states in the eastern USA
(n = 47) and Texas (n = 60). Persons
identiﬁed with aggressive periodontitis,
or with antibiotic use in the past 6 mo,
were excluded. Approval for the study
was provided by the Temple University
Human Subjects Protections Institu-
tional Review Board.
Microbial sampling and transport
Subgingival plaque specimens were
obtained by the diagnosing periodon-
tists, who followed a standardized
sampling protocol, before treatment
from three to ﬁve deep ( 6 mm)
periodontal pockets in each subject
that exhibited bleeding on probing
during the initial diagnostic evalua-
tion. After isolation with cotton rolls,
and removal of saliva and supragingi-
val deposits, one or two sterile, absor-
bent, paper points (Johnson &
Johnson, East Windsor, NJ, USA)
were advanced into each selected peri-
odontal site for approximately 10 s.
Upon removal, all paper points per
study subject were pooled in a glass
vial containing six to eight small glass
beads and 2.0 mL of anaerobically
prepared and stored VMGA III trans-
port medium (13), which possesses a
high preservation capability for oral
microorganisms during postsampling
transit to the laboratory (13,14). The
subgingival samples were then
transported within 24 h to the OMTS
Laboratory, which is licensed for
high-complexity bacteriological analy-
sis by the Pennsylvania Department
of Health. The OMTS Laboratory is
also federally certiﬁed by the United
States Department of Health and
Human Services to be in compliance
with Clinical Laboratory Improve-
ment Amendments-mandated proﬁ-
ciency testing, quality control, patient
test management, personnel require-
ments and quality assurance stan-
dards required of clinical laboratories
engaged in diagnostic testing of
human specimens in the USA (15).
All laboratory procedures were
performed by personnel who were
blinded to the clinical status of the
study subjects and their inclusion in
the present analysis.
Microbial culture and incubation
At the OMTS Laboratory, the speci-
men vials were warmed to 35°C to liq-
uefy the VMGA III transport medium,
and sampled microorganisms were
mechanically dispersed from the paper
points with a Vortex mixer, which was
used at the maximal setting for 45 s.
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Serial, 10-fold dilutions of the dis-
persed bacteria were prepared in
M€oller’s VMG I anaerobic dispersion
solution, comprised of prereduced,
anaerobically sterilized, 0.25% tryp-
tose, 0.25% thiotone E peptone and
0.5% NaCl (13). Then, 0.1-mL dilu-
tion aliquots were spread, with a sterile
bent glass rod, onto nonselective
enriched Brucella blood agar (EBBA)
primary isolation plates (16), com-
posed of 4.3% Brucella agar supple-
mented with 0.3% bacto-agar, 5%
deﬁbrinated sheep blood, 0.2% hemo-
lyzed sheep red blood cells, 0.0005%
hemin and 0.00005% menadione, and
onto selective trypticase soy–bacitracin
–vancomycin (TSBV) agar (17). The
inoculated EBBA plates were incu-
bated at 35°C for 7 d in a Coy anaero-
bic chamber (Coy Laboratory
Products, Ann Arbor, MI, USA) con-
taining 85% N2, 10% H2 and 5% CO2,
and the TSBV plates were incubated at
35°C for 3 d in air + 5% CO2.
Test species identification
Total anaerobic viable counts, and
counts of the test species Porphyro-
monas gingivalis, Prevotella interme-
dia/nigrescens, other Prevotella species
(including Prevotella melaninogenica
and nonpigmented Prevotella species),
Fusobacterium nucleatum, Parvimonas
micra, Capnocytophaga species, Strep-
tococcus constellatus, Centipeda peri-
odontii, Enterococcus faecalis and
staphylococci, were made on nonse-
lective EBBA primary isolation plates
using a ring-light magnifying loupe,
presumptive phenotypic methods pre-
viously described (18–21) and the
RapID ANA II (Innovative Diagnostic
Systems, Atlanta, GA, USA) micro-
method kit system for selected isolates.
Aggregatibacter actinomycetemcomi-
tans, gram-negative enteric rods/pseu-
domonads and Candida species were
quantitated on selective TSBV agar, as
previously described (16,17). The pro-
portional recovery of each test species
was ascertained in each subject by cal-
culating the percentage of test species
colony-forming units relative to total
subgingival anaerobic viable counts, as




Additional 0.1 mL aliquots of sub-
gingival sample dilutions were inocu-
lated onto EBBA primary isolation
plates supplemented with either 2 lg/
mL of amoxicillin, which was previ-
ously established as a susceptibility
breakpoint for aminopenicillin antibi-
otics (22), or a combination of 2 lg/
mL of amoxicillin plus 2 lg/mL of
the b-lactamase-inhibitor, clavulanic
acid (23), followed by anaerobic incu-
bation. Direct colony suspensions
(equivalent to a 0.5 McFarland stan-
dard) of pure A. actinomycetemcomi-
tans isolates from selective TSBV
were subcultured onto these media as
their identiﬁcation is frequently
obscured within mixed bacterial popu-
lations on nonselective EBBA primary
isolation plates (17).
A surface-overlay technique was
used to add clavulanic acid, at a con-
centration of 2 lg/mL, to amoxicillin-
containing EBBA primary isolation
plates (24). Using a sterile glass rod,
0.1 mL of a fresh 400-lg/mL solution
of clavulanic acid, prepared by dis-
solving 4.2 mg of a 95.3% pure lith-
ium clavulanate powder (provided by
SmithKline Beecham, Collegeville,
PA, USA) into 10 mL of sterile 0.1 M
phosphate buﬀer (pH 6.0), was evenly
spread over the surfaces of EBBA
plates supplemented with 20 mL of
amoxicillin. The plates were held at
room temperature for 30 min to allow
surface drying and subsurface drug
diﬀusion, and then inoculated with
subgingival plaque specimens.
Test species positive for b-lactam-
ase production were presumptively
identiﬁed by growth on EBBA pri-
mary isolation plates supplemented
with amoxicillin alone and by no
growth on EBBA primary isolation
plates containing both amoxicillin and
clavulanic acid (6,7). A subset of 50
such presumptively identiﬁed isolates
was subjected to a nitroceﬁn-based
qualitative chromogenic disk assay
(BBL Ceﬁnase; BD Diagnostic Sys-
tems, Sparks, MD, USA), following
the manufacturer’s instructions, to
conﬁrm the presence of b-lactamase
activity.
In vitro antibiotic-resistance testing
Aliquots (0.1 mL) of subgingival sam-
ple dilutions were also inoculated
onto EBBA primary isolation plates
supplemented with metronidazole at a
susceptibility breakpoint concentra-
tion of 4 lg/mL (22), and incubated
anaerobically for 7 d, in order to
assess in vitro resistance to metronida-
zole among b-lactamase-producing
clinical isolates. In vitro resistance to
metronidazole was deﬁned as test
species growth on metronidazole-
supplemented EBBA primary isola-
tion plates (16,20,25,26). Bacteroides
thetaiotaomicron ATCC 29741, Clos-
tridium perfringens ATCC 13124 and
a multiantibiotic-resistant clinical
periodontal isolate of F. nucleatum
were employed as positive and nega-
tive quality controls for the antibiotic
resistance testing. All antimicrobials
were obtained as pure powder from
Sigma-Aldrich (St Louis, MO, USA).
Data analysis
Descriptive analyses were used to cal-
culate mean subject age and standard
deviation values, the occurrence and
proportional cultivable recovery of
test species in subjects, the occurrence
and proportional recovery of b-lac-
tamase-producing organisms in sub-
jects, and the occurrence in subjects
of in vitro metronidazole drug resis-
tance among the subgingival clinical
isolates. Data analysis was performed
using the SAS 9.2 for Windows (SAS
Institute, Inc., Cary, NC, USA) statis-
tical software package.
Results
A subset of 50 test species, presump-
tively identiﬁed as b-lactamase positive
by their growth on amoxicillin-supple-
mented EBBA primary isolation plates
and by no growth on amoxicillin plus
clavulanic acid-supplemented EBBA
primary isolation plates, were all con-
ﬁrmed as b-lactamase-producing orga-
nisms using the nitroceﬁn chromogenic
disk assay (data not shown).
A total of 294 (52.1%) study sub-
jects yielded b-lactamase-producing
subgingival test species. P. intermedia/
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nigrescens, F. nucleatum and other
Prevotella species were most fre-
quently identiﬁed as b-lactamase-
positive species, with 51.0% of
all study subjects with cultivable
P. intermedia/nigrescens, 24.6% with
F. nucleatum and 66.2% with other
Prevotella species exhibiting b-lactam-
ase-producing strains of these species
(Table 1). Beta-lactamase production
was also found among 0.8% of P. mi-
cra species, 2.0% of Capnocytophaga
species and 5.0% of gram-negative
enteric rods/pseudomonads in culture-
positive subjects (Table 1).
A single b-lactamase-producing
subgingival test species was recovered
from 236 (80.3%) subjects, whereas
54 (18.4%) and four (1.3%) subjects
each yielded two and three diﬀerent
b-lactamase-producing test species,
respectively (Fig. 1).
Subgingival proportions of b-lac-
tamse-positive P. intermedia/nigres-
cens, F. nucleatum and P. micra
averaged 6.7–9.9%, whereas mean
subgingival recovery levels of <1%
were found for b-lactamase-positive
isolates of other Prevotella species
and for Capnocytophaga species
(Table 1). Three-hundred and ﬁfty-
three (98.9%) of the 357 b-lactamase-
producing subject test species recov-
ered (Table 1) were susceptible in vi-
tro to 4 lg/mL of metronidazole,
except for one P. intermedia/nigres-
cens strain, one F. nucleatum strain
and gram-negative enteric rods/pseu-
domonads in two subjects.
All recovered strains of P. gingiva-
lis, A. actinomycetemcomitans, S. con-
stellatus, C. periodontii, E. faecalis,




These ﬁndings conﬁrm and extend pre-
vious studies revealing subgingival
b-lactamase-producing bacteria to be
present in a majority of patients
with chronic periodontitis (3–11). A
strength of the present study is that it
assessed the largest group, to date, of
subjects with chronic periodontitis for
subgingival b-lactamase-producing
bacteria (n = 564); similar, previous,
investigations have collectively exam-
ined a total of only 255 subjects with
chronic periodontitis (3,5–11). The
present study data also evaluated a pri-
vate dental practice-based convenience
sample of subjects with chronic peri-
odontitis originating from a wider geo-
graphic region than in previous reports
from the USA on subgingival b-lactam-
ase activity (2,3,5), which may permit
the ﬁndings to be more generalizable to
a broader range of USA community
population groups.
Owing to the instability of clavulan-
ic acid in agar-dilution plates stored
for more than 3 d (24), a surface-
overlay technique was used in this study
to add clavulanic acid to amoxicillin-
containing EBBA primary isolation
plates immediately before in vitro test-
ing. As clavulanic acid binds irrevers-
ibly to b-lactamases and prevents
inactivation of b-lactam antibiotics
(23), microbial growth patterns on
these plates were compared with those
on EBBA plates supplemented with
amoxicillin only as a presumptive
method for detecting b-lactamase-
positive subgingival bacterial species.
This approach was validated with con-
ﬁrmatory nitroceﬁn chromogenic disk
testing for b-lactamase activity from
presumptively detected subgingival
bacterial species in previous studies
(6,7), as well as on a subset of such sub-
ject isolates in the present study.
In this study, 52.1% of subjects
with untreated chronic periodontitis











standard error) Range %
Prevotella intermedia/nigrescens 449 (79.6) 229 (40.6/51.0) 9.6  0.8 0.001–62.1
Fusobacterium nucleatum 293 (52.0) 72 (12.8/24.6) 6.7  0.9 0.001–29.4
Other Prevotella speciesa 68 (12.1) 45 (8.0/66.2) 0.6  0.5 0.001–24.2
Capnocytophaga species 251 (44.5) 5 (0.9/2.0) 0.3  0.1 0.002–0.6
Parvimonas micra 495 (87.8) 4 (0.7/0.8) 9.9  3.9 1.5–19.7
Enteric rods/pseudomonads 40 (7.1) 2 (0.4/5.0) 1.7  0.8 0.9–2.5
Porphyromonas gingivalis 197 (34.9) 0 0 0
Aggregatibacter
actinomycetemcomitans
85 (15.1) 0 0 0
Streptococcus constellatus 267 (47.3) 0 0 0
Centipeda periodontii 4 (0.7) 0 0 0
Enterococcus faecalis 5 (0.9) 0 0 0
Staphylococcus species 4 (0.7) 0 0 0
aIncludes Prevotella melaninogenica and nonpigmented Prevotella species.
bAmong all study subjects.
cSpecies growth on amoxicillin-supplemented enriched Brucella blood agar (EBBA) primary isolation plates, with no growth on similar
plates with a clavulanic acid overlay.
dAmong species-positive study subjects.
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yielded b-lactamase-producing subgin-
gival bacteria, which is at the lower
end of the prevalence rates of 53.2–
100% reported in previous studies (3,5
–11). This may be because of diﬀer-
ences in periodontal disease severity,
treatment status and recent systemic
antibiotic usage among the evaluated
subjects with chronic periodontitis
and the microbiological methods
employed. For example, some previ-
ous studies evaluated only subjects
with ‘refractory’ chronic periodontitis,
responding poorly to conventional
mechanical periodontal therapy (5,8).
As systemic antimicrobial therapy is
frequently employed in such patients
(27), which is positively correlated
with increased subgingival b-lactamase
activity (3), it is not surprising that a
greater occurrence of b-lactamase-pro-
ducing subgingival bacteria would be
reported for patients with ‘refractory’
periodontitis compared with patients
with untreated chronic periodontitis
and without antibiotic use within the
past 6 mo, as in the present study. In
this regard, the 52.1% occurrence of
subgingival b-lactamase-producing
bacteria in the present study is similar
to the 48% rate documented among
21 patients with chronic periodontitis
not exposed to antibiotic therapy over
the previous 12 mo (3). Moreover, a
higher occurrence of subgingival b-lac-
tamase would also be expected among
subjects with chronic periodontitis
from countries, such as in south-
ern Europe, with greater antibiotic
over-the-counter access and con-
sumption rates than found in the USA
(28).
P. intermedia/nigrescens, F. nuclea-
tum and other Prevotella species were
the most frequently identiﬁed b-lac-
tamase-positive species in the present
study, consistent with previous inves-
tigations (3,5–10). Subgingival recov-
ery of cultivable enzyme-producing
strains of P. intermedia/nigrescens and
F. nucleatum averaged 9.6% and
6.7%, respectively, of total anaerobic
viable counts in b-lactamase-positive
subjects, whereas other Prevotella spe-
cies occurred in lower proportions,
averaging <1%. P. micra, Capnocy-
tophaga species and gram-negative
enteric rods/pseudomonads were also
found to be b-lactamase positive in
some study subjects. Interestingly, all
197 strains of P. gingivalis found in
subjects in the present study were b-
lactamase negative, in agreement with
most previous studies of subgingival
isolates (6,9,29). In contrast, 7.7% of
26 subgingival P. gingivalis strains
were reported to be b-lactamase-posi-
tive in one study (30), and 25.5% of
51 strains in another study (31) were
found in vitro to be resistant to amox-
icillin, but susceptible to amoxicillin/
clavulanic acid, indicative of b-lac-
tamase production. Additional b-lac-
tamase-positive microbial species and
subjects would probably be identiﬁed
using more sensitive methods, such as
molecular analysis of bacterial 16S
ribosomal RNA gene sequences (5,8)
or b-lactamase-encoding genes
(4,10,32,33), than the culture-based
procedures employed in the present
study.
This study also did not classify
b-lactamase phenotypes, test for
b-lactamase groups resistant to clavul-
anic acid or quantitate the strength of
subgingival b-lactamase activity pres-
ent in b-lactamase-positive subjects
(1,2). Additionally, the private prac-
tice periodontists who diagnosed the
study subjects were not calibrated in
their assessments, although support
for their diagnosis of severe chronic
periodontitis was evidenced by their
identiﬁcation for microbiological sam-
pling of three or more periodontal
sites per subject with probing depths
of  6 mm, which strongly correlates
(94.1% positive predictive value) with
the presence of severe periodontal
attachment loss in adults (34).
The presence of b-lactamase activ-
ity in periodontal pockets poses
potentially important therapeutic
implications relative to the control of
mixed populations of subgingival
periodontal bacterial pathogens in
dental plaque bioﬁlms. Enzymatic
degradation of b-lactam antibiotics
may permit subgingival perpetuation
of b-lactamase-producing microbial
species and other organisms in the
subgingival microbiota that otherwise
would be suppressed by b-lactam anti-
biotics (1). An increasing prevalence
of b-lactamase activity among oral
bacterial isolates has been reported
(35), which is largely thought to be
the result of plasmid and transposon-
mediated conjugal transfer and dis-
semination of b-lactamase-encoding
genes among microorganisms surviv-
ing following selective pressure from
b-lactam antibiotics (1). Beta-lacta-
mases may predispose systemic peni-
cillin monotherapy, unprotected by
b-lactamase inhibitors, to oral cavity
treatment failures, such as recalcitrant
orofacial infections (36,37) and peri-
odontal surgical ﬂap necrosis (38), as
well as enhance periodontal abscess
risk in untreated periodontitis subjects
(39,40).
Penicillin and amoxicillin are
among the systemic antibiotics most
frequently prescribed by periodontists
(41). However, relatively little re-
search attention has been given to
their adjunctive use in periodontal
therapy in the absence of b-lactamase
inhibitors (42,43), with systemic phen-







Fig. 1. Occurrence of one or more periodontal bacterial pathogens producing b-lactamase
among 294 b-lactamase-positive subjects with chronic periodontitis.
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signiﬁcant treatment beneﬁts in a clin-
ical trial of patients with aggressive
periodontitis (44). It is noteworthy
that subgingival bacterial isolates
resistant to 2 lg/mL of amoxicillin
were found to show a transient
increase from a pretreatment baseline
of 0.5% to 35% (a 70-fold increase),
over the course of an adjunctive 14-d
systemic amoxicillin drug regimen, in
patients with chronic periodontitis
(45). In that study, P. intermedia/
nigrescens and P. melaninogenica,
often identiﬁed as b-lactamase-pro-
ducing species in the present and pre-
vious studies (3,5–10), were found to
be among the most prevalent amoxi-
cillin-resistant organisms (45). The
extent to which bacterial b-lactamase
activity contributed to these in vivo
microbiological shifts was not add-
ressed in the study and remains to be
delineated in future investigations.
Finally, the present study found
98.9% of recovered subgingival
b-lactamase-producing bacteria to be
susceptible in vitro to 4 lg/mL of
metronidazole, an observation consis-
tent with previous reports (3,5,8). As
a result, metronidazole suppression of
b-lactamase-positive microbial species
may, in part, help to protect concur-
rently administered amoxicillin from
in vivo degradation by bacterial b-lac-
tamases, better enabling pharmaco-
logically active amoxicillin to reach
penicillin-binding proteins on bacte-
rial cell membranes to exert antimi-
crobial eﬀects (1), and contributing to
the documented clinical and microbio-
logical beneﬁts of systemic amoxicillin
plus metronidazole in periodontal
therapy (46–49). However, this may
not occur in patients from certain
geographic regions, such as Columbia,
where marked in vitro metronidazole
resistance may be found among b-lac-
tamase-positive subgingival isolates of
P. gingivalis, P. intermedia/nigrescens,
P. melaninogenica and F. nucleatum
(31).
In conclusion, the occurrence of
b-lactamase-positive subgingival
bacterial species in more than one-
half of subjects with severe chronic
periodontitis raises questions about
the therapeutic potential of single-
drug regimens with b-lactam anti-
biotics in periodontal therapy. The
in vitro eﬀectiveness of metronidazole
against nearly all recovered b-lactam-
ase-producing subgingival bacterial
species further supports clinical
periodontitis treatment strategies
involving the combination of systemic
amoxicillin plus metronidazole.
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